Delivery Order SPE2DB25D9320-SPE2DB25FWEZP

Award Date 3/31/25
Potential Completion Date 4/1/25
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,339.18 contract is for the delivery of XTANDI 80 MG TABLET 60S, a specialized pharmaceutical product, with a performance period ending on April 1, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,339.18, is for the supply of XTANDI 80 MG TAB 60S, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This...
This is a firm fixed-price delivery order for pharmaceutical products and medical supplies awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $16,678.36 contract covers the delivery of XTANDI 40 MG TABLET 120S to military healthcare facilities through March 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,169.59 contract is for the delivery of 60 tablets of the prescription medication Xtandi 80 mg. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
This is a delivery order contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $8,339.18 firm fixed-price contract is for the supply of XTANDI 80 MG TABLET 60S, a specialized pharmaceutical product, with a performance period through March 24, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,169.59, is for the delivery of XTANDI 80 MG TABLET 60S, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999. The contract covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This specific delivery order, valued at $11,193.31, is for the supply of XTANDI 80 MG TAB 60S, a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,169.59 contract is for the delivery of XTANDI 80 MG TABLET 60S, a specialized prescription medication, to support the medical supply needs of military healthcare facilities. The award is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $12,934.05 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $12,508.77, is for the delivery of XTANDI 40 MG TABLET 120S to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which...
  • SPE2DB25D9320
    Indefinite Delivery Contract
  • SPE2DB25D9320-SPE2DB25FWEZP
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,169.59 contract is for the delivery of XTANDI 80 MG TABLET 60S, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities.

DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This contract award is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 6/30/25, 10:50 AM